Sacha Gnjatic

List of Publications by Year in Descending Order

227 papers	20,578 citations	68 h-index	142 g-index
269 ext. papers	25,250 ext. citations	10.9 avg, IF	6.22 L-index

#	Paper	IF	Citations
227	Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity.. *Science Translational Medicine*, **2022**, 14, eabm7853	17.5	10
226	Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.. *The Lancet Gastroenterology and Hepatology*, **2022**,	18.8	7
225	Spatial CRISPR genomics identifies regulators of the tumor microenvironment.. *Cell*, **2022**,	56.2	7
224	CTIM-09. PHASE I STUDY OF PD-L1 INHIBITION WITH AVELUMAB AND LASER INTERSTITIAL THERMAL THERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA. *Neuro-Oncology*, **2021**, 23, vi51-vi51	1	
223	Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Commpass Study. *Blood*, **2021**, 138, 2691-2691	2.2	
222	Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. *Cancer Cell*, **2021**, 39, 1442-1444	24.3	25
221	Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. *Modern Pathology*, **2021**, 34, 1456-1467	9.8	59
220	Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. *Clinical Cancer Research*, **2021**, 27, 4287-4300	12.9	9
219	Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy **2021**, 9,		3
218	BRAF-induced senescence drives Langerhans cell histiocytosis pathophysiology. *Nature Medicine*, **2021**, 27, 851-861	50.5	11
217	Divergent early antibody responses define COVID-19 disease trajectories **2021**,		3
216	Fr492 SIGNIFICANTLY REDUCED MORTALITY IN COVID-19 PATIENTS WITH GASTROINTESTINAL MANIFESTATIONS. *Gastroenterology*, **2021**, 160, S-330	13.3	78
215	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. *Gastroenterology*, **2021**, 160, 2435-2450.e34	13.3	45
214	Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies. *Translational Lung Cancer Research*, **2021**, 10, 3079-3092	4.4	2
213	A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. *Clinical Cancer Research* , **2021**, 27, 2470-2480	12.9	9
212	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. *Nature Reviews Clinical Oncology*, **2021**, 18, 345-362	19.4	148
211	A streamlined whole blood CyTOF workflow defines a circulating immune cell signature of COVID-19. *Cytometry Part A: the Journal of the International Society for Analytical Cytology*, **2021**, 99, 446-461	4.6	7

210	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. *Blood*, **2021**, 137, 3212-3217	2.2	9
209	Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network. *Clinical Cancer Research*, **2021**, 27, 5072-5083	12.9	3
208	Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC. *Clinical Cancer Research*, **2021**, 27, 5062-5071	12.9	1
207	Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies. *Gastroenterology*, **2021**, 161, 715-718.e4	13.3	55
206	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma **2021**, 9,		4
205	Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children. *Nature Communications*, **2021**, 12, 4854	17.4	12
204	Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). *Clinical Cancer Research*, **2021**, 27, 5038-5048	12.9	1
203	A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. *OncoImmunology*, **2020**, 9, 1847846	7.2	7
202	The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation **2020**, 8,		54
201	Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City. *Clinical Infectious Diseases*, **2020**, 71, 2933-2938	11.6	100
200	MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. *European Radiology*, **2020**, 30, 3759-3769	8	35
199	A COMMON PITUITARY AUTOANTIBODY IN TWO PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR-MEDIATED HYPOPHYSITIS: ZCCHC8. *AACE Clinical Case Reports*, **2020**, 6, e151-e160	0.7	4
198	Integrated Cytof, Scrna-Seq and Cite-Seq Analysis of Bone Marrow Immune Microenvironment in the Mmrf Commpass Study. *Blood*, **2020**, 136, 28-29	2.2	1
197	Architecture of Sample Preparation and Data Governance of Immuno-Genomic Data Collected from Bone Marrow and Peripheral Blood Samples Obtained from Multiple Myeloma Patients. *Blood*, **2020**, 136, 17-18	2.2	
196	Identification and Validation of CD138- Multiple Myeloma Immune and Tumor Subpopulations Using Cross Center Scrna-Seq Data. *Blood*, **2020**, 136, 15-15	2.2	
195	Characterization of Plasma and Immune Cells Molecular Landscape That Play a Role in Rapid Progression of Multiple Myeloma Using Cross Center Scrna-Seq Study. *Blood*, **2020**, 136, 6-8	2.2	
194	CIMAC-CIDC tissue imaging harmonization.. *Journal of Clinical Oncology*, **2020**, 38, 3125-3125	2.2	1
193	Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer. *Oncotarget*, **2020**, 11, 2669-2683	3.3	2

192	510. Elevated IL-1□level as a predictor of inflammation and death in COVID-19. *Open Forum Infectious Diseases*, **2020**, 7, S320-S321	1	
191	A phase II study of atezolizumab and cobimetinib in PD-1/PD-L1 inhibitor resistant or refractory non-small cell lung cancer: ETCTN #10166.. *Journal of Clinical Oncology*, **2020**, 38, TPS9638-TPS9638	2.2	0
190	CD3 and CD20 immune cell densities in primary tumors, lymph node metastasis, and recurrent disease samples of head and neck squamous cell carcinoma.. *Journal of Clinical Oncology*, **2020**, 38, 6551-6551	2.2	0
189	CIMAC-CIDC CyTOF harmonization.. *Journal of Clinical Oncology*, **2020**, 38, e15242-e15242	2.2	1
188	A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward **2020**,		3
187	Multiplexed Immunohistochemical Consecutive Staining on Single Slide (MICSSS): Multiplexed Chromogenic IHC Assay for High-Dimensional Tissue Analysis. *Methods in Molecular Biology*, **2020**, 2055, 497-519	1.4	14
186	An inflammatory cytokine signature helps predict COVID-19 severity and death **2020**,		43
185	A Streamlined CyTOF Workflow To Facilitate Standardized Multi-Site Immune Profiling of COVID-19 Patients **2020**,		6
184	Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C) **2020**,		16
183	Cytotoxic lymphocytes are dysregulated in multisystem inflammatory syndrome in children **2020**,		4
182	Gastrointestinal involvement attenuates COVID-19 severity and mortality **2020**,		19
181	Tumoral and immune heterogeneity in an anti-PD-1-responsive glioblastoma: a case study. *Journal of Physical Education and Sports Management*, **2020**, 6,	2.8	2
180	Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. *Clinical Cancer Research*, **2020**, 26, 450-464	12.9	28
179	Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma. *Cancer Immunology Research*, **2020**, 8, 70-80	12.5	19
178	Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). *Cell*, **2020**, 183, 982-995.e14	56.2	248
177	A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. *Journal of Hematology and Oncology*, **2020**, 13, 94	22.4	76
176	Proliferation of HIV-infected renal epithelial cells following virus acquisition from infected macrophages. *Aids*, **2020**, 34, 1581-1591	3.5	6
175	Sampling the host response to SARS-CoV-2 in hospitals under siege. *Nature Medicine*, **2020**, 26, 1157-1158	30.5	8

174	400 GM-CSF AUTOANTIBODIES PRECEDE THE DEVELOPMENT OF CROHN'S DISEASE AND PREDICT COMPLICATED PHENOTYPE AT DIAGNOSIS. *Gastroenterology*, **2020**, 158, S-74	13.3	3
173	Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I-conceptual challenges **2020**, 8,		5
172	An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nature Medicine*, **2020**, 26, 1636-1643	50.5	895
171	Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II-practical challenges **2020**, 8,		2
170	Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy. *Cell*, **2019**, 178, 1493-1508.e20	56.2	219
169	First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. *Clinical Cancer Research*, **2019**, 25, 5808-5817	12.9	38
168	First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1. *Cancer Immunology, Immunotherapy*, **2019**, 68, 1211-1222	7.4	14
167	Host tissue determinants of tumour immunity. *Nature Reviews Cancer*, **2019**, 19, 215-227	31.3	94
166	A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.. *Journal of Clinical Oncology*, **2019**, 37, 9538-9538	2.2	3
165	Phase I study of PD-L1 inhibition with avelumab and laser interstitial thermal therapy in patients with recurrent glioblastoma.. *Journal of Clinical Oncology*, **2019**, 37, TPS2074-TPS2074	2.2	3
164	Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: a meta-analysis. *Oncotarget*, **2019**, 10, 7142-7155	3.3	15
163	Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy. *Blood*, **2019**, 134, 3093-3093	2.2	
162	Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple Myeloma. *Blood*, **2019**, 134, 4367-4367	2.2	
161	High Dimensional Immune Profiling in Smoldering Multiple Myeloma Identifies Novel Organizing Features of the Tumor Microenvironment. *Blood*, **2019**, 134, 4384-4384	2.2	
160	Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine-Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma. *Cancer Immunology Research*, **2019**, 7, 658-669	12.5	8
159	Single-cell immune landscape of human atherosclerotic plaques. *Nature Medicine*, **2019**, 25, 1576-1588	50.5	247
158	Immunohistochemical Detection of T Lymphocytes in Formalin-fixed Paraffin-embedded Tissues. *Applied Immunohistochemistry and Molecular Morphology*, **2019**, 27, 581-583	1.9	16
157	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. *European Urology*, **2018**, 73, 751-759	10.2	67

156	A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission.. *Journal of Clinical Oncology*, **2018**, 36, 5553-5553	2.2	4
155	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists for resected stage IIB-IV melanoma.. *Journal of Clinical Oncology*, **2018**, 36, e15171-e15171	2.2	1
154	IMMU-60. MAPPING TUMORAL AND IMMUNE HETEROGENEITY IN PD-1 RESPONSIVE GLIOBLASTOMA. *Neuro-Oncology*, **2018**, 20, vi135-vi135	1	78
153	Radiotherapy induces responses of lung cancer to CTLA-4 blockade. *Nature Medicine*, **2018**, 24, 1845-1851	50.5	379
152	NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. *Gynecologic Oncology*, **2017**, 145, 420-425	4.9	42
151	Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. *Cell*, **2017**, 169, 750-765.e17	56.2	629
150	Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging. *Scientific Reports*, **2017**, 7, 2452	4.9	58
149	First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. *Journal of Immunotherapy*, **2017**, 40, 302-306	5	38
148	Cancer Immunotherapy: From local to global. *Nature Nanotechnology*, **2017**, 12, 840-841	28.7	7
147	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. *Nature*, **2017**, 551, 512-516	50.4	533
146	Immunotherapy biomarkers 2016: overcoming the barriers **2017**, 5, 29		17
145	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy **2017**, 5, 44		139
144	Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS).. *Journal of Clinical Oncology*, **2017**, 35, 11006-11006	2.2	9
143	Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients.. *Journal of Clinical Oncology*, **2017**, 35, 3090-3090	2.2	2
142	A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers.. *Journal of Clinical Oncology*, **2017**, 35, TPS3114-TPS3114	2.2	4
141	DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC).. *Journal of Clinical Oncology*, **2017**, 35, 300-300	2.2	5
140	MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. *Oncotarget*, **2017**, 8, 14719-14735	5.2	16
139	In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. *Science Immunology*, **2016**, 1, aaf6925	28	93

138	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge, Napoli, December 5th 2015 **2016**, 4,		78
137	Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck. *Head and Neck*, **2016**, 38, 1008-16	4.2	13
136	A multimodal imaging workflow to visualize metal mixtures in the human placenta and explore colocalization with biological response markers. *Metallomics*, **2016**, 8, 444-52	4.5	13
135	Single-agent LV305 to induce anti-tumor immune and clinical responses in patients with advanced or metastatic sarcoma and other cancers expressing NY-ESO-1.. *Journal of Clinical Oncology*, **2016**, 34, 3093-3093	2.2	1
134	Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer.. *Journal of Clinical Oncology*, **2016**, 34, 357-357	2.2	20
133	Prognostic effects of peripheral and tumor-infiltrating T-cell repertoire diversity in ovarian cancer.. *Journal of Clinical Oncology*, **2016**, 34, 5546-5546	2.2	
132	Protein Expression Analysis of Melanocyte Differentiation Antigen TRP-2. *American Journal of Dermatopathology*, **2016**, 38, 201-7	0.9	1
131	A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF. *Gastroenterology*, **2016**, 151, 710-723.e2	13.3	40
130	HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. *Gynecologic Oncology*, **2016**, 142, 158-162	4.9	5
129	Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. *Immunity*, **2016**, 44, 924-38	32.3	544
128	Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma. *Cancer Immunology Research*, **2015**, 3, 278-287	12.5	63
127	Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity. *Frontiers in Immunology*, **2015**, 6, 67	8.4	94
126	Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas. *Cancer Immunology, Immunotherapy*, **2015**, 64, 1193-203	7.4	14
125	NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus. *International Journal of Cancer*, **2015**, 136, E590-601	7.5	33
124	The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 191, 377-90	10.2	140
123	Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. *Scientific Reports*, **2015**, 5, 14896	4.9	60
122	Consensus nomenclature for CD8 T cell phenotypes in cancer. *OncoImmunology*, **2015**, 4, e998538	7.2	101
121	Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1.. *Journal of Clinical Oncology*, **2015**, 33, 3021-3021	2.2	7

120	A first-in-human phase 1 dose-escalating trial of G305 in patients with solid tumors expressing NY-ESO-1.. *Journal of Clinical Oncology*, **2015**, 33, 3073-3073	2.2	2
119	Impact of gemcitabine + cisplatin + ipilimumab on circulating immune cells in patients (pts) with metastatic urothelial cancer (mUC).. *Journal of Clinical Oncology*, **2015**, 33, 4586-4586	2.2	4
118	Window of opportunity trial of HPV E7 antigen-expressing Listeria-based therapeutic vaccination prior to robotic surgery for HPV-positive oropharyngeal cancer.. *Journal of Clinical Oncology*, **2015**, 33, TPS6088-TPS6088	2.2	1
117	Poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 VG in patients with melanoma.. *Journal of Clinical Oncology*, **2015**, 33, e14034-e14034	2.2	
116	Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells. *Cancer Immunology Research*, **2014**, 2, 341-50	12.5	37
115	Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. *Cancer Immunology Research*, **2014**, 2, 37-49	12.5	144
114	Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates. *Cancer Immunology Research*, **2014**, 2, 404-9	12.5	7
113	Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 832-44	10.2	340
112	Classification of current anticancer immunotherapies. *Oncotarget*, **2014**, 5, 12472-508	3.3	301
111	Intratumoral checkpoint subversion as a strategy for minimizing adverse effects: Harvesting the power of TILs without harvesting TILs. *OncoImmunology*, **2014**, 3, e27580	7.2	2
110	Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer. *Cancer Research*, **2014**, 74, 7205-16	10.1	74
109	Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma. *Cancer Immunology Research*, **2014**, 2, 547-58	12.5	9
108	Recombinant (rec) MAGE-A3 Protein Immunotherapy and Peripheral Blood Lymphocyte (PBL) Reconstitution Induce Strong Antigen-Specific Humoral and Cellular Immune Responses in Patients Undergoing Autologous Stem Cell Transplantation (ASCT) for Consolidation of Multiple Myeloma (MM). *Blood*, **2014**, 124, 1184-1184	2.2	7
107	Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma.. *Journal of Clinical Oncology*, **2014**, 32, TPS9119-TPS9119	2.2	1
106	Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. *PLoS ONE*, **2014**, 9, e104099	3.7	48
105	Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.. *Journal of Clinical Oncology*, **2014**, 32, 9086-9086	2.2	
104	A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence. *Cancer Immunology, Immunotherapy*, **2013**, 62, 1327-34	7.4	1
103	Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. *Clinical Cancer Research*, **2013**, 19, 6112-25	12.9	50

102	The abscopal effect associated with a systemic anti-melanoma immune response. *International Journal of Radiation Oncology Biology Physics*, **2013**, 85, 293-5	4	304
101	Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. *Cancer Immunology Research*, **2013**, 1, 340-50	12.5	53
100	Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. *Cancer Immunology Research*, **2013**, 1, 235-44	12.5	75
99	A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. *Sarcoma*, **2013**, 2013, 168145	3.1	114
98	Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes. *European Journal of Immunology*, **2013**, 43, 989-1000	6.1	8
97	Ipilimumab for patients with advanced mucosal melanoma. *Oncologist*, **2013**, 18, 726-32	5.7	117
96	A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. *Cancer Immunity*, **2013**, 13, 3		9
95	Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination. *International Journal of Cancer*, **2012**, 130, 584-92	7.5	36
94	Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. *Blood*, **2012**, 119, 3097-104	2.2	58
93	Phase I clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity. *Clinical Cancer Research*, **2012**, 18, 5449-59	12.9	42
92	Therapeutic administration of a synthetic CpG oligodeoxynucleotide triggers formation of anti-CpG antibodies. *Cancer Research*, **2012**, 72, 4304-10	10.1	17
91	Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients. *Cancer Immunology, Immunotherapy*, **2012**, 61, 2207-14	7.4	12
90	Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. *Cancer Research*, **2012**, 72, 1672-82	10.1	40
89	Cancer classification using the Immunoscore: a worldwide task force. *Journal of Translational Medicine*, **2012**, 10, 205	8.5	538
88	Immunologic correlates of the abscopal effect in a patient with melanoma. *New England Journal of Medicine*, **2012**, 366, 925-31	59.2	1503
87	Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 5797-802	11.5	153
86	Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells. *Journal of Immunology*, **2012**, 188, 3851-8	5.3	28
85	Split T-cell tolerance as a guide for the development of tumor antigen-specific immunotherapy. *OncoImmunology*, **2012**, 1, 405-407	7.2	3

84	Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. *Clinical Cancer Research*, **2012**, 18, 6497-508	12.9	201
83	Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. *Journal of Immunotherapy*, **2012**, 35, 89-97	5	100
82	Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer. *Journal of Immunotherapy*, **2012**, 35, 513-21	5	38
81	NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. *PLoS ONE*, **2012**, 7, e38783	3.7	66
80	MAGE-A3 is highly expressed in a subset of colorectal cancer patients. *Cancer Immunity*, **2012**, 12, 16		32
79	Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors. *PLoS ONE*, **2011**, 6, e23651	3.7	14
78	Trypanosoma cruzi as an effective cancer antigen delivery vector. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 19695-700	11.5	29
77	Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 16723-8	11.5	270
76	Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity. *Journal of Immunology*, **2011**, 186, 1218-27	5.3	88
75	Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. *Cancer Research*, **2011**, 71, 5670-7	10.1	294
74	Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy. *Cancer Immunity*, **2011**, 11, 1		9
73	Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas. *Clinical Cancer Research*, **2010**, 16, 3562-70	12.9	40
72	Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 3093-8	11.5	32
71	Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 7875-80	11.5	580
70	Seromic profiling of ovarian and pancreatic cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 5088-93	11.5	141
69	Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. *International Journal of Cancer*, **2010**, 126, 909-18	7.5	78
68	Toll-like receptor agonists: are they good adjuvants?. *Cancer Journal (Sudbury, Mass)*, **2010**, 16, 382-91	2.2	115
67	NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. *International Journal of Cancer*, **2010**, 127, 381-93	7.5	41

66	Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. *Cancer Immunity*, **2010**, 10, 4		29
65	Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. *Cancer Immunity*, **2010**, 10, 1		32
64	CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. *Nucleic Acids Research*, **2009**, 37, D816-9	20.1	257
63	NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. *Clinical Cancer Research*, **2009**, 15, 2130-9	12.9	68
62	Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination. *Journal of Immunology*, **2009**, 183, 4800-8	5.3	32
61	Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays. *Journal of Immunological Methods*, **2009**, 341, 50-8	2.5	65
60	Autoantibodies against cancer antigens. *Methods in Molecular Biology*, **2009**, 520, 11-9	1.4	43
59	CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 20410-5	11.5	291
58	Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. *New England Journal of Medicine*, **2008**, 358, 2698-703	59.2	702
57	Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 1650-5	11.5	141
56	Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. *Journal of Immunology*, **2008**, 181, 776-84	5.3	207
55	Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. *Clinical Cancer Research*, **2008**, 14, 2740-8	12.9	85
54	Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. *Cancer Research*, **2008**, 68, 5948-54	10.1	69
53	RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. *Blood*, **2008**, 111, 1357-65	2.2	170
52	Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. *Blood*, **2008**, 111, 1404-12	2.2	27
51	Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. *Journal of Immunotherapy*, **2008**, 31, 849-57	5	48
50	Inducing efficient cross-priming using antigen-coated yeast particles. *Journal of Immunotherapy*, **2008**, 31, 607-19	5	13
49	Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1. *Cancer Immunology, Immunotherapy*, **2008**, 57, 1185-95	7.4	19

48	Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination. *International Journal of Cancer*, **2007**, 121, 2042-8	7.5	25
47	Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 12837-42	11.5	212
46	CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 3967-72	11.5	354
45	Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. *Blood*, **2007**, 109, 1103-12	2.2	138
44	Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. *Journal of Immunotherapy*, **2007**, 30, 847-54	5	35
43	LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. *Cancer Immunity*, **2007**, 7, 16		38
42	Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. *Cancer Immunity*, **2007**, 7, 11		65
41	PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. *Cancer Immunity*, **2007**, 7, 18		49
40	Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011. *International Journal of Cancer*, **2006**, 118, 668-74	7.5	10
39	In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope. *Clinical Cancer Research*, **2006**, 12, 1921-7	12.9	38
38	Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 14453-8	11.5	182
37	Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination. *Journal of Immunology*, **2006**, 176, 6340-6	5.3	50
36	NY-ESO-1: review of an immunogenic tumor antigen. *Advances in Cancer Research*, **2006**, 95, 1-30	5.9	265
35	Ex-vivo analysis of CD8+ T cells infiltrating colorectal tumors identifies a major effector-memory subset with low perforin content. *Journal of Clinical Immunology*, **2006**, 26, 447-56	5.7	28
34	In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. *Journal of Clinical Investigation*, **2006**, 116, 1946-54	15.9	127
33	Host Immune Responses Against CT Antigens in Multiple Myeloma Patients.. *Blood*, **2006**, 108, 3492-3492	2.2	1
32	Protein and DNA-Based Vaccines With the NY-ESO-1 Antigen in Cancer Patients. *Journal of Immunotherapy*, **2005**, 28, 659	5	1
31	CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. *Blood*, **2005**, 106, 1008-11	2.2	151

30	Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 18538-43	11.5	1722
29	Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. *Clinical Cancer Research*, **2005**, 11, 8055-62	12.9	285
28	NY-ESO-1 expression and immunogenicity in esophageal cancer. *Clinical Cancer Research*, **2004**, 10, 6551-8	12.9	53
27	The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. *Clinical Cancer Research*, **2004**, 10, 6946-55	12.9	61
26	NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. *Cancer Research*, **2004**, 64, 2199-204	10.1	85
25	Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. *Journal of Immunology*, **2004**, 172, 3289-96	5.3	160
24	IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 14467-72	11.5	32
23	Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 10697-702	11.5	373
22	Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. *European Journal of Immunology*, **2004**, 34, 2919-29	6.1	60
21	Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. *Cancer Immunity*, **2004**, 4, 11		23
20	Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. *Cancer Immunity*, **2004**, 4, 12		19
19	HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones. *Cancer Immunity*, **2004**, 4, 15		5
18	Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 8862-7	11.5	168
17	Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs. *Journal of Immunology*, **2003**, 170, 1191-6	5.3	46
16	Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. *Journal of Immunological Methods*, **2003**, 278, 57-66	2.5	45
15	NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. *Cancer Immunity*, **2003**, 3, 10		28
14	NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. *Cancer Research*, **2003**, 63, 6076-83	10.1	173
13	Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. *Cancer Immunity*, **2003**, 3, 19		33

12	Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 10629-34	11.5	70
11	CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 11813-8	11.5	79
10	Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. *Journal of Clinical Investigation*, **2002**, 110, 1813-22	15.9	64
9	Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. *Cancer Immunity*, **2002**, 2, 12		14
8	Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. *Journal of Immunology*, **2000**, 165, 948-55	5.3	148
7	Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. *Journal of Experimental Medicine*, **2000**, 191, 625-30	16.6	182
6	Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules. *European Journal of Immunology*, **1995**, 25, 1638-42	6.1	34
5	Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience		80
4	Serological response to COVID-19 vaccination in IBD patients receiving biologics		6
3	Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patients		3
2	Application of a 27-protein candidate cardiovascular surrogate endpoint to track risk ascendancy and resolution in COVID-19		1
1	Perturb-map enables CRISPR genomics with spatial resolution and identifies regulators of tumor immune composition		2